Ninlaro - Ixazomib - Ninlaro Multiple Myeloma - Ixazomib Myeloma


What is Ninlaro?

Ninlaro®, also known as ixazomib, is a type of cancer drug called a proteasome inhibitor. Ninlaro is in the same class of drugs as Velcade® (bortezomib, Takeda Oncology) and is made by the same company. It is considered to be a second-generation proteasome inhibitor because it has improved characteristics and activity over Velcade.

Ninlaro is an oral medication.

The Multiple Myeloma Research Consortium (MMRC) has been instrumental in the development of Ninlaro. The MMRC facilitated a clinical trial for newly diagnosed patients with Ninlaro in combination with Revlimid® (lenalidomide, Celgene) and dexamethasone and has initiated 4 additional trials in patients with relapsed or refractory myeloma, residual myeloma, as maintenance therapy following autologous stem cell transplant, and as a treatment for patients with plasma cell leukemia or extramedullary disease.

uses2 side effects2 dosing2 clinical studies2